|
T8825 |
Capmatinib 2HCl.H2O
|
INCB28060 2HCl.H2O,INC-280 2HCl.H2O,NVP-INC280 2HCl.H2O |
c-Met/HGFR
|
|
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. |
|
T8416 |
Capmatinib xHCl
|
INCB28060,Capmatinib hydrochloride(free base),INC280 |
c-Met/HGFR
|
|
Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activit... |
|
T1963 |
Capmatinib
|
NVP-INC280,INC-280,INCB28060 |
Apoptosis
,
c-Met/HGFR
|
|
Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. |
|
T4260 |
Capmatinib 2HCl
|
INC-280 2HCl,INCB28060 2HCl |
c-Met/HGFR
|
|
Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-... |
|
T71382 |
KRC-108
|
|
|
|
KRC-108 is a multiple kinase inhibitor. KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met. KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than wild type c-Met. The anti-proliferative... |
